Background and Context
Menopause — defined as the permanent cessation of menstruation following 12 consecutive months of amenorrhoea — typically occurs between the ages of 45 and 55 in Ireland, with a median age of 51 years. Perimenopause, the transitional phase preceding menopause, can begin 4–10 years earlier and is characterised by irregular menstrual cycles and fluctuating hormone levels. Premature ovarian insufficiency (POI), affecting approximately 1% of women under 40, represents a distinct clinical category requiring separate consideration.[1]
In June 2025, Ireland became one of the first countries in Europe to provide hormone replacement therapy free of charge at the point of dispensing to all women resident in the State. Enacted through the Health Insurance (Amendment) and Health (Provision of Menopause Products) Act 2024, and launched on 1 June 2025, the scheme is funded by a €20 million annual Budget 2025 allocation and covers all HRT products and dispensing fees where HRT has been clinically prescribed. Over 1,800 community pharmacies had joined the scheme by July 2025.[2,3]
Since 1 June 2025, all women ordinarily resident in Ireland who are prescribed HRT by a healthcare provider to alleviate symptoms associated with any stage of menopause — including perimenopause, postmenopause, early menopause, premature menopause and induced menopause — can obtain it free of charge from participating pharmacies via the Drugs Payment Scheme or Medical Card Scheme. The scheme saves women an estimated €360–€840 annually. Information at gov.ie/HRT.
This policy development significantly lowers the access barrier to HRT in Ireland, making it clinically important that all practitioners — including those not specialising in menopause — are equipped to discuss the evidence for and against HRT, understand which patients are most appropriate candidates, and recognise the role of genetic and functional medicine assessment in personalising treatment decisions.
The Physiology of Menopause
The primary driver of menopausal symptoms is the decline in ovarian oestrogen production — specifically 17β-oestradiol — as follicular reserves are depleted. This decline in oestrogen has systemic consequences: reduced bone mineral density, changes in lipid metabolism, vasomotor instability (hot flushes and night sweats), urogenital atrophy, and effects on mood, cognition and sleep architecture.[4]
Progesterone production, which declines earlier in perimenopause as ovulatory cycles become irregular, contributes to sleep disruption and mood changes independently of oestrogen. Testosterone, produced in smaller quantities in the ovaries and adrenal glands, also declines through the menopause transition and contributes to reduced libido, fatigue and cognitive symptoms.[5]
The severity of menopausal symptoms varies considerably between individuals. Approximately 75% of women experience vasomotor symptoms, of whom 25% describe these as severe and significantly impairing quality of life. Symptom duration averages 7.4 years but can exceed a decade in a significant proportion of women.[6]
What HRT Does: Mechanism and Formulations
HRT replaces the oestrogen — and where indicated, progesterone and/or testosterone — that the ovaries no longer produce in sufficient quantities. It does not restore fertility or reverse the menopausal transition; it addresses the physiological consequences of hormone deficiency.
Oestrogen
Oestrogen is the primary active component of HRT. Available formulations include oral tablets, transdermal patches, gels, sprays and subcutaneous implants. Transdermal delivery avoids first-pass hepatic metabolism, resulting in a more physiological oestrogen profile and — critically — avoiding the increased venous thromboembolism (VTE) risk associated with oral oestrogen.[7]
Progestogen
In women with a uterus, progestogen must be added to oestrogen therapy to protect the endometrium from hyperplasia. Progestogens vary significantly in their pharmacological profile. Micronised progesterone (Utrogestan) most closely resembles endogenous progesterone and is associated with lower thrombotic and breast cancer risk compared with synthetic progestogens (progestins) such as medroxyprogesterone acetate (MPA).[8]
Testosterone
Testosterone replacement in menopausal women remains unlicensed in Ireland and the UK for female indications, though off-label use is supported by the British Menopause Society and NICE. Evidence supports its use for hypoactive sexual desire disorder (HSDD), with emerging data on mood, cognition and musculoskeletal outcomes.[9]
Clinical Evidence: Benefits of HRT
Vasomotor Symptoms
HRT is the most effective treatment for vasomotor symptoms (hot flushes and night sweats). A 2017 Cochrane systematic review of 24 RCTs (n=3,329) confirmed that oestrogen reduces hot flush frequency by approximately 75% and severity significantly compared with placebo — a magnitude of effect no non-hormonal intervention has replicated to date.[10]
Bone Health
Oestrogen is a potent inhibitor of osteoclast activity. HRT reliably prevents postmenopausal bone loss and reduces fracture risk. The Women's Health Initiative (WHI) demonstrated a 33% reduction in hip fracture and 23% reduction in total fractures in women taking combined HRT.[11] Current NICE guidelines (NG23, updated 2019) recommend HRT as a first-line option for prevention of osteoporosis in menopausal women who also have symptoms.[12]
Cardiovascular Risk — The Timing Hypothesis
The relationship between HRT and cardiovascular disease is substantially determined by when HRT is initiated relative to menopause onset — the "timing hypothesis" or "window of opportunity." Observational data and re-analysis of WHI data consistently demonstrate that HRT initiated within 10 years of menopause or before age 60 is associated with reduced cardiovascular mortality and coronary heart disease risk. Initiation beyond this window, in older women with pre-existing subclinical atherosclerosis, may increase risk.[13]
Urogenital and Sexual Health
Genitourinary syndrome of menopause (GSM) — urogenital atrophy causing vaginal dryness, dyspareunia and urinary symptoms — responds well to both systemic and local oestrogen. Local vaginal oestrogen carries minimal systemic absorption and is appropriate for women in whom systemic HRT is contraindicated.[14]
Mood and Cognition
Perimenopausal women have a two- to fourfold increased risk of depressive symptoms compared with premenopausal women, independent of prior psychiatric history.[15] RCT evidence supports the efficacy of oestradiol for perimenopausal depression (Freeman et al., JAMA Psychiatry 2006). The relationship between HRT and dementia risk is complex and incompletely resolved; current evidence does not support initiating HRT primarily for cognitive protection but does not indicate increased risk when initiated early.[16]
| Outcome | Evidence | Quality |
|---|---|---|
| Vasomotor symptoms | ~75% reduction in hot flush frequency vs placebo | Cochrane SR · Robust |
| Bone fracture prevention | Hip fracture risk reduced 33% (WHI) | Large RCT · Robust |
| CV risk reduction (early initiation) | Reduced CHD mortality if initiated <10 years post-menopause | Observational + RCT re-analysis |
| Urogenital atrophy (GSM) | Significant symptom improvement with local/systemic oestrogen | Multiple RCTs · Robust |
| Perimenopausal depression | Oestradiol superior to placebo in perimenopause | RCT · Moderate |
| Sleep quality | Improvement via vasomotor symptom reduction | RCTs · Indirect evidence |
| Libido / HSDD | Testosterone effective for HSDD (unlicensed in Ireland) | Systematic review · Moderate |
Risks and Contraindications: A Critical Evaluation
Breast Cancer
Breast cancer risk is the most discussed concern around HRT and requires careful contextualisation. The 2019 Collaborative Group analysis (Lancet, Beral et al., n=108,647) found that combined oestrogen-progestogen HRT is associated with increased breast cancer risk, with approximately 1 additional case per 50 women taking combined HRT for 5 years from age 50. Oestrogen-only HRT (in hysterectomised women) showed no significant increase or a small reduction in risk in some analyses.[17]
The absolute risk increase must be contextualised: the Lancet 2019 analysis was observational and relied on heterogeneous historical datasets including oral oestrogen and synthetic progestins now less commonly prescribed. More recent data consistently show that transdermal oestrogen combined with micronised progesterone carries a lower risk profile than oral oestrogen with synthetic progestogens. Risk also varies substantially by individual factors including BMI, alcohol intake, physical activity and family history — none of which were individually adjusted for in the Collaborative Group analysis. Practitioners should apply individualised risk-benefit assessment rather than class-level risk attribution.
Venous Thromboembolism
Oral oestrogen increases VTE risk by approximately twofold. Transdermal oestrogen at standard doses does not appear to increase VTE risk — a finding supported by multiple case-control studies and the ESTHER study.[7] This distinction is clinically significant when prescribing for women with obesity, immobility or personal/family history of VTE.
Absolute Contraindications
- Current or recent oestrogen-receptor-positive breast cancer
- Undiagnosed vaginal bleeding
- Active or recent VTE (unless on anticoagulation — specialist assessment required)
- Active liver disease with abnormal liver function
- Untreated endometrial cancer
- Uncontrolled hypertension (relative — transdermal may be appropriate once controlled)
Who Is HRT Appropriate For?
Current guidance from NICE (NG23), the British Menopause Society and the International Menopause Society supports offering HRT to symptomatic menopausal women in whom there are no contraindications, after individual risk-benefit discussion. Key clinical scenarios:
- Perimenopausal women with significant vasomotor, mood or sleep symptoms — strongest evidence base; early initiation supports cardiovascular and bone benefit
- Women with premature ovarian insufficiency (POI) — HRT is strongly recommended until at least the average age of natural menopause (51 years) for cardiovascular and bone protection, regardless of symptom severity[1]
- Women within 10 years of menopause or under 60 — the timing hypothesis supports cardiovascular benefit in this group; benefits clearly outweigh risks in most cases
- Women with established osteoporosis or high fracture risk — HRT is an effective alternative to bisphosphonates, particularly in younger postmenopausal women
- Women with significant genitourinary syndrome of menopause — local vaginal oestrogen is effective and appropriate even in women who decline systemic HRT
HRT is generally less appropriate as a first-line choice — and requires specialist input — in women with a personal history of ER-positive breast cancer, active VTE, severe liver disease or unexplained uterine bleeding.
The Role of Genetics in HRT Suitability
Individual variation in HRT response, tolerability and risk is partly explained by genetic polymorphisms affecting hormone metabolism, receptor sensitivity and coagulation pathways. This is an area of active research rather than established clinical protocol, but several clinically relevant genetic factors are emerging.
CYP1A2 and CYP3A4 — Oestrogen Metabolism
Oestrogen is metabolised primarily via cytochrome P450 enzymes — particularly CYP1A2, CYP3A4 and CYP1B1. Polymorphisms in these genes influence the ratio of oestrogen metabolites produced. The 2-hydroxy pathway (favourable) versus the 16α-hydroxy pathway (potentially proliferative) ratio varies between individuals and has been associated with differential breast cancer risk. Women with CYP1B1 4326CG polymorphisms may metabolise oestrogen towards more proliferative metabolites, though the clinical implications for HRT prescribing remain investigational.[18]
COMT — Catechol-O-Methyltransferase
COMT is responsible for methylation and inactivation of catechol oestrogens. The COMT Val158Met polymorphism (rs4680) significantly affects enzyme activity — the Met/Met genotype (low COMT activity) results in slower clearance of catechol oestrogens, potentially increasing exposure to reactive quinone metabolites associated with DNA damage. This may be relevant to individual breast cancer risk assessment in the context of HRT.[19]
Factor V Leiden and Prothrombin Gene Mutation
Factor V Leiden (FVL, rs6025) and prothrombin G20210A mutation significantly increase baseline VTE risk. In carriers of these thrombophilias, oral oestrogen is contraindicated due to compounded VTE risk. Transdermal oestrogen does not appear to carry the same elevated VTE risk even in FVL carriers, making genetic thrombophilia screening clinically relevant in women considering HRT — particularly those with a personal or family history of VTE.[20]
BRCA1/2
Women with BRCA1/2 mutations who undergo risk-reducing bilateral salpingo-oophorectomy (RRBSO) should generally be offered HRT until the natural age of menopause. Current evidence does not demonstrate that short-term HRT in BRCA carriers increases breast cancer risk above baseline, and the cardiovascular and bone protection benefits of HRT in surgically menopausal women are substantial. This remains an area of active clinical debate and specialist-led decision making is essential.[21]
What Genetic Assessment Can Offer
Pharmacogenomic panels assessing CYP450 enzyme polymorphisms, COMT, MTHFR, thrombophilia genes and oestrogen receptor variants are increasingly available through functional medicine laboratories including Nordic Laboratories (DNALife™). These panels do not determine whether HRT should or should not be prescribed — that remains a clinical decision. They can inform formulation choice (transdermal vs oral), progestogen type, route of administration and monitoring intervals, and may identify women in whom detailed haematological or oncological specialist input is warranted before initiating HRT.
The Functional Medicine Assessment: What It Adds
The free HRT scheme in Ireland will increase the number of women commencing HRT without specialist menopause assessment. For many women this is entirely appropriate — straightforward perimenopausal symptoms in a healthy woman with no contraindications represent a clear indication for HRT. However, a proportion of women presenting for HRT will have more complex clinical pictures in which a functional medicine assessment adds significant value.
1. Comprehensive Hormone Profiling
Standard GP assessment of menopause typically involves FSH and oestradiol measurement — a snapshot of a highly variable hormonal state. Functional medicine assessment may include DUTCH (Dried Urine Test for Comprehensive Hormones) analysis, which provides 24-hour urinary hormone metabolite profiling, enabling assessment of oestrogen metabolism pathways (2-OH vs 16α-OH ratio), progesterone status, adrenal function and cortisol pattern. This is particularly relevant in women with complex symptoms, poor HRT response or elevated breast cancer concern.[18]
2. Thyroid Function — The Overlooked Overlap
Hypothyroidism and perimenopause share overlapping symptom profiles — fatigue, weight gain, low mood, cognitive impairment and menstrual irregularity. Subclinical hypothyroidism (TSH 2.5–10 mIU/L with normal T4) is prevalent in women over 40 and may be missed on standard TSH-only screening. Full thyroid panel assessment — including free T3, free T4, anti-TPO and anti-thyroglobulin antibodies — is warranted in women presenting with complex perimenopausal symptoms before attributing all symptoms to oestrogen deficiency.[5]
3. Adrenal Function and HPA Axis
The adrenal glands become an increasingly important source of androgen precursors (DHEA-S) and cortisol as ovarian function declines. Chronic psychosocial stress and HPA axis dysregulation — common in perimenopausal women managing competing life demands — can exacerbate vasomotor symptoms and impair sleep independently of oestrogen levels. Assessment of cortisol diurnal rhythm and DHEA-S may identify women in whom adrenal support is a meaningful adjunct to HRT.[5]
4. Nutritional Status and Bone Health
Vitamin D deficiency is highly prevalent in Irish women — estimated at 40–50% of the population — and compounds postmenopausal bone loss independently of oestrogen status. Magnesium, vitamin K2, boron and omega-3 fatty acids all play roles in bone mineral density maintenance and metabolic health through menopause. Assessment of nutritional status enables targeted supplementation that complements HRT's bone-protective effects.[22]
5. Lifestyle Factors with Independent Evidence
Several lifestyle interventions have published RCT evidence for menopause symptom management that is independent of — and complementary to — HRT:
- Resistance exercise: Reduces vasomotor symptom frequency and severity; preserves lean mass and bone mineral density; improves mood and sleep quality (multiple RCTs)[22]
- Dietary pattern: Mediterranean dietary pattern associated with reduced vasomotor symptom severity and cardiovascular risk in postmenopausal women (PREDIMED sub-analysis)
- Sleep optimisation: Cognitive behavioural therapy for insomnia (CBT-I) is evidence-based for menopausal insomnia, particularly where vasomotor symptoms have been controlled by HRT but sleep disruption persists
- Alcohol reduction: Alcohol is a documented trigger for hot flushes and independently elevates breast cancer risk — a clinically important discussion in the context of HRT initiation
- Stress management: Mind-body interventions including mindfulness-based stress reduction (MBSR) have RCT evidence for vasomotor symptom reduction (Carmody et al., 2011)
6. Identifying Women Who May Not Respond to Standard HRT
Women with poor response to standard HRT formulations may have identifiable functional medicine explanations: impaired oestrogen metabolism (assessable via DUTCH), COMT or MTHFR polymorphisms affecting methylation capacity, significant gut dysbiosis affecting the oestrobolome (the gut microbial genes responsible for oestrogen recirculation via enterohepatic cycling), or persistent HPA axis dysregulation masking symptomatic improvement. These are not contraindications to HRT — they are modifiable factors that, when addressed, may significantly improve treatment outcomes.
Conclusion
The introduction of free HRT in Ireland from June 2025 is a landmark development in women's health policy, removing a significant financial barrier to accessing an evidence-based treatment with well-documented benefits for symptom management, bone health, cardiovascular protection and quality of life.
The evidence supports offering HRT to symptomatic menopausal women without contraindications, with particular emphasis on transdermal oestrogen and micronised progesterone as the lower-risk formulation choice. Risk-benefit assessment must be individualised — blanket class-level risk attribution, particularly around breast cancer, does not reflect the current published evidence and should not be the basis for withholding an effective treatment.
Genetic assessment of oestrogen metabolism pathways and thrombophilia risk can meaningfully inform formulation and monitoring decisions in appropriate patients. Functional medicine evaluation — comprehensive hormone profiling, thyroid and adrenal assessment, nutritional status, genetic metabolic panel — adds a layer of personalisation that standard prescribing pathways do not provide, and is particularly valuable in women with complex presentations, poor HRT response or elevated individual risk factors.
The functional medicine approach is not proposed as an alternative to HRT where HRT is indicated. It is proposed as a complementary framework that addresses the breadth of factors influencing menopause experience and HRT response, and that builds the metabolic and physiological foundation for a healthy menopause transition — with or without pharmacological support.
